Indiana 2026 Regular Session

Indiana House Bill HB1114

Introduced
1/5/26  
Refer
1/5/26  
Report Pass
1/20/26  
Engrossed
1/29/26  
Refer
2/2/26  
Refer
2/12/26  
Report Pass
2/19/26  
Enrolled
2/24/26  
Passed
3/3/26  
Chaptered
3/3/26  

Caption

Coverage for certain cancer prescriptions.

Impact

If enacted, HB 1114 will directly influence the insurance coverage protocols regarding cancer treatment within state employee health plans. The bill reinforces the importance of immediate access to effective medications for advanced cancer patients without imposing additional barriers related to prior drug failures. The change is expected to support better health outcomes by allowing timely access to necessary treatments based on peer-reviewed best practices rather than administrative hurdles.

Summary

House Bill 1114 aims to amend the Indiana Code concerning health insurance provisions for state employees. Specifically, it focuses on the coverage of prescription drugs for the treatment of advanced, metastatic cancer and associated conditions. The bill stipulates that state employee health plans will not require individuals to have previously failed treatments before obtaining coverage for these specific prescription drugs. This legislative effort is intended to enhance access to essential medications for employees affected by severe health conditions.

Sentiment

The general sentiment surrounding HB 1114 appears supportive, particularly among advocates for cancer patients and healthcare access. Proponents highlight the importance of ensuring that individuals dealing with severe health challenges are not forced to navigate complex prior authorization processes that could delay treatment. Further, the sentiment reflects a recognition of the necessity for policies that prioritize patient health over bureaucratic constraints.

Contention

There are potential points of contention related to the bill, particularly concerning the balance between insurance cost controls and providing necessary coverage. Opponents may raise concerns about the fiscal impact on state health plans if requirements for drug approval are relaxed. Although no significant opposition was noted in the documented discussions or voting records, as with any significant healthcare legislation, there could be financial implications that warrant careful consideration and analysis.

Companion Bills

No companion bills found.

Previously Filed As

IN HB1062

Coverage for certain cancer prescriptions.

IN HB1061

Coverage for cancer screening.

IN HB1358

Coverage of prescription pain medications.

IN HB1200

Opioid prescriptions.

IN HB1298

Contraceptive coverage.

IN HB1138

Coverage for obesity treatments.

IN SB0184

Coverage for clean dietary supplements.

IN HB1299

Funding for breast cancer research.

IN HB1202

Medicaid coverage for treatment of obesity.

IN HB1552

Coverage for treatment of chronic diseases.

Similar Bills

AZ HB2291

Opioids; containers; labeling; requirements; repeal

CA AB577

Health care coverage: antisteering.

RI H8318

Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.

RI S2889

Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.

HI SB2751

Relating To Workers' Compensation.

HI HB2225

Relating To Health.

TX SB493

Relating to protection of certain disclosures and communications by pharmacists and pharmacies regarding prescription drug benefits.

RI H5866

Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.